Skip to main content

A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia.

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

October 1, 2015

End Date

May 10, 2024
 

Administered By

Duke Cancer Institute

Awarded By

Dana-Farber Cancer Institute

Start Date

October 1, 2015

End Date

May 10, 2024